for the AIDS Clinical Trials Group (ACTG) 5303 team Objective: The objective was to determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART).
Introduction
The central nervous system (CNS) is a privileged compartment protected by the blood-brain barrier, which reduces influx of potentially toxic and therapeutic substances, including antiretroviral drugs. Despite this protective barrier, HIV enters the CNS within days of infection, trafficking into the CNS through infected T cells and monocytes [1] . In a minority of individuals, HIV establishes an autonomous, infection in the CNS [2] . Genetically distinct, or compartmentalized, HIV in the CNS has been correlated with HIV-associated neurocognitive disorders (HAND) [3] . In the current era of combination ART, subtle or mild neurocognitive deficits are prevalent in almost 40% of those who have effective treatment and despite having successfully suppressed systemic viral replication [4] .
Although the mechanism of neuronal injury underlying HAND remains to be completely elucidated, HIV replication within the CNS is thought to drive an inflammatory process by inducing cytokine production that impairs neuronal functioning and eventually leads to neuronal cell death [1, 5] . Up to 10% of individuals receiving antiretroviral therapy (ART) experience ongoing HIV replication and its consequences in the CNS despite having undetectable HIV RNA in plasma, a phenomenon known as CNS escape [6] [7] [8] . HIV may also establish a quiescent, nonreplicating infection within the CNS, possibly contributing to inflammation, neuronal dysfunction, and ultimately HAND [9] . Controlling HIV replication and viral load in the CNS and associated inflammatory processes could lead to improved neurocognitive outcomes and reduce the current prevalence of mild HAND.
The main coreceptor for HIV entry into target cells is the chemokine coreceptor 5 (CCR5). The antiretroviral maraviroc (MVC) is an effective inhibitor of CCR5. MVC is also thought to have anti-inflammatory effects, as CCR5 is a primary ligand of macrophage inflammatory protein-1a, which is proinflammatory [10] . In a rat model, CCR5 inhibition downregulated proinflammatory matrix metalloproteinase-9 [11] , and in a macaque model MVC reduced replicating and latent simian immunodeficiency virus as well as monocyte and macrophage activation in the brain [12] . Small clinical studies in HIV-1-infected individuals have also suggested that intensifying ART with MVC may improve neuronal integrity [13] or neurocognitive performance [14] . On the other hand, CCR5 deficiency has been associated with worse outcomes during CNS viral infections [15, 16] , and an animal study reported increased microglial activation with MVC, suggesting the possibility of exacerbating neuronal disease with chronic MVC use [17] . To ascertain the effects of MVC on HAND, we investigated changes in neuropsychological performance in AIDS Clinical Trials Group (ACTG) study A5303 [ClinicalTrials.gov. Identifier: NCT 01400412], a randomized, double-blind, clinical trial of MVC versus tenofovir disoproxil fumarate (TDF)-containing ART in treatment-naive HIV-1-infected participants. Our hypothesis was that MVC would be associated with greater improvement in neuropsychological performance compared with TDF as MVC has potential antiinflammatory effects in addition to antiviral effects.
Methods

Study design
As detailed in the primary publication [18] , A5303 was a phase 2, prospective, double-blind, placebo-controlled, randomized multicenter, 48-week clinical trial conducted between January 2012 and June 2014 at 33 ACTG and four Adolescent Trials Network research sites in the United States. Individuals whom the site investigator felt could not complete the neurocognitive protocol because of HIV or other illness, and those with HIV-associated neurological disease as documented by their clinical provider were excluded. The study enrolled 262 ARTnaive HIV-1-infected participants (18 years or older) with plasma viral load greater than 1000 copies/ml and R5 tropism on the Trofile phenotypic assay (Monogram Biosciences, South San Francisco, California, USA). The Institutional Review Board of each study site approved the protocol. Each study participant provided a written informed consent (Clinicaltrials.gov identifier NCT01400412).
Study procedures
Participants received MVC 150 mg or TDF 300 mg (1 : 1 ratio), each combined with darunavir 800 mg, ritonavir 100 mg, and emtricitabine 200 mg, once daily. Randomization was stratified by screening viral load less than or at least 100 000 copies/ml and age less than 30 or at least 30 years.
Neurocognitive assessment
Neuropsychological performance was assessed at study entry, week 24 [25, 26] ), 'Fine Motor Skills' (Grooved Pegboard bilateral [27, 28] ), and 'Verbal Memory' (Delayed Recall -HVLT-R [20] , Recognition -HVLT-R [20] ). Participants also completed an assessment of activities of daily living (ADL) to assess functional ability [30] .
The tests were averaged into two summary scores: total zscore and global deficit score (GDS) [31] . Total z-score was computed through the average of the 15 individual test z-scores. Individual test z-scores were computed by subtracting the test raw score from the demographically corrected normative score adjusted for age, education, sex, and race where appropriate, then dividing by the normative SD [32] . Resulting z-scores vary around zero, which reflects average performance, positive scores denote better than average performance, and negative scores reflect impaired performance. GDS was computed through the average of the individual test deficit scores. Increasing positive scores from zero reflect increasing deficits or impairment; 1 reflects mild impairment whereas 5 reflects severe impairment. Deficit scores set to 0 any normal or above normal performances, and thus avoid issues of summing positive and negative performances [29] . Deficit scores were computed as follows: 0 (z > À1); 1 (À1.5 z À1); 2 (À2.0 z < À1.5); 3 (À2.5 z < À2.0); 4 (À3.0 z < À2.5); and 5 (z À3.0); missing if z-score is missing. For domains, z-score and deficit scores were computed. The total ADL score is the sum of 16 ADL scores (excluding score 8, not applicable). Question 5 of the ADL questionnaire has scores 1, 2, and 3 so that it was changed to 0, 1, and 2.
To ensure that the neuropsychological tests were done consistently across the study sites, all staff assigned to administer the tests received appropriate training and certification under the supervision of a neuropsychologist (K.R.R.). Staff training was supported by several mechanisms: in-person training at the annual ACTG meetings, video training films, and PowerPoint presentations. After the initial training and completion of a webbased certification test, subsequent review of the training materials and recertification of the research staff occurred at least annually.
Neurocognitive impairment
Mild neurocognitive impairment was defined as having at least two neurocognitive domains with the mean domain deficit scores of 1 or more. Moderate neurocognitive impairment was defined as having at least two neurocognitive domains with the mean domain deficit scores of 2 or more. We also defined impairment according to conventional HAND categorization [33] ; Normal (deficit scores <1 for all domains, ADL ¼ 0); asymptomatic neurocognitive impairment (ANI, deficit scores !1 for at least two domains, ADL ¼ 0); mild neurocognitive disorder (MND, deficit scores !1 for at least two domains and ADL ! 1, or deficit scores !2 for two domains and ADL 0-3); (HAD, deficit scores !2 for two domains, ADL ! 4).
Other study procedures
Routine study visits for safety, virologic, and immunologic assessments occurred at week 4 (AE7 days), and weeks 16, 24, 36, and 48, all AE 14 days. Adherence to study medications was assessed by self-report at all study visits after entry except week 36.
Statistical analyses
The 24 and 48-week changes in the individual test zscores, the total z-score, and the GDS were compared by Wilcoxon rank sum tests between study treatment arms, and by Kruskal-Wallis test between the baseline impairment groups. The changes from baseline, week 24 and week 48 total z-scores were assessed by Wilcoxon signed rank tests. All analyses were as-treated and included only participants who remained on their randomized MVC or TDF component by week 48 without an interruption in treatment of more than 10 weeks with available data for both baseline and week 48. If participants were unable to perform any individual test because of a reason unrelated to HIV-associated neurological disease their individual test z-scores were treated as missing. All statistical tests were two-sided and interpreted at the 5% nominal level of significance without adjustment for multiple comparisons. Analyses were conducted using SAS statistical software 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Baseline characteristics
Total 230 participants were randomized to the MVC (N ¼ 119) versus TDF arm (N ¼ 111) ( Table 1 ). The arms were comparable by sex (total 91% male), and age [median age 33 years; interquartile range (IQR), [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . In all 82% were English speakers, 9% were Spanish speakers, and 70% had at least some college education. Baseline characteristics were similar between the study arms, except for a chance racial imbalance with more non-Hispanic blacks in the MVC arm (total 44% non-Hispanic white, and 31% non-Hispanic black, P < 0.05). Both arms were also comparable by HIV viral load (total median plasma HIV RNA 4.5 log 10 copies/ ml; IQR 4.0, 5.0) and current immune functioning (total CD4 þ cell count 389 cells/ml; IQR 293, 508).
At baseline, individual z-scores, total z-scores, GDS scores, and well as domain z-scores (fine motor, speed of processing, executive functioning, verbal learning, verbal memory, and attention score) were similar between the MVC and TDF arms. For example, there were no significant differences in GDS between the arms at baseline (median MVC 0.33; IQR 0.07, 0.73 versus median TDF 0.33; IQR 0.13, 0.64). At baseline, 55% of participants were normal and 45% had a HAND diagnosis. ANI was found in 12.2%, MND in 30.6%, and 2.2% HAD. None of the participants was unable to perform a test because of a reason related to HIVassociated neurological disease.
Neurocognitive change by treatment arm
The primary analysis was to compare changes in neurocognitive performance (total z-score and GDS) by arm from baseline to weeks 24 and 48. Most neurocognitive test performances improved through week 48 and were significantly better than the baseline performance. The median (IQR) GDS was 0.3 (0.1, 0.7) at baseline and 0.2 (0.0, 0.5) at week 48. The median (IQR) 48-week change in the GDS was À0.08 (À0.27, 0) (P value < 0.001). There were no significant differences in neurocognitive performance for z-score or GDS between the MVC and TDF arms at 24 weeks or 48 weeks ( Table 2 ; Fig. 1 ).
Neurocognitive change by baseline neurocognitive status
Those with GDS normal baseline functioning had very little changes, whereas those with GDS mild and moderate impairment improved from baseline to 48 weeks (P value < 0.001; Fig. 2 ). The median (IQR) 48week change in GDS was 0.0 (À0.1, 0.1) for unimpaired (n ¼ 126), À0.2 (À0.3, À0.1) for mildly impaired (n ¼ 69), and À0.4 (À0.7, À0.2) for moderately impaired (n ¼ 35). For HAND diagnoses, among participants with ANI, MND, or HAD at baseline, there was greater improvement in those with more severe HAND at baseline (P < 0.001). The median (IQR) 48-week change in GDS was 0.0 (À0.1, 0.1) for unimpaired (n ¼ 126), 2318 AIDS 2016, Vol 30 No 15 Global deficit score 116 À0.1 (À0.2, 0.1) 108 À0.1 (À0. À0.2 (À0.3, 0.1) for ANI (n ¼ 28), À0.3 (À0.6, À0.1) for MND (n ¼ 70), and À0.7 (À0.7, À0.3) for HAD (n ¼ 5). Fifteen ANI participants (53.6%) at baseline, 33 MND participants (48.5%), and three HAD participants (60.0%) became unimpaired at week 48.
Discussion
ART initiation has been shown to improve overall neurocognitive performance [34, 35] . We found that ART initiation with either MVC or TDF-containing regimens significantly improved neurocognitive functioning. The neurocognitive improvement is a combination of antiretroviral effects because of viral suppression, as well as learning and practice effects [36] . Those with worse baseline functioning had greater improvement. As neurocognitively impaired individuals generally have poorer learning abilities and less practice effects, our findings suggest that improvements in this study were driven more by ART as opposed to learning/ practice effects.
We found no apparent advantage for neurocognitive performance with MVC over TDF containing regimens. The primary results of A5303 also showed similar efficacy in suppressing plasma HIV-1 viremia with both the MVC and TDF-containing antiretroviral regimens [18] .
The neuropathogenesis of HAND is likely related to neuronal dysfunction and death because of neuroinflammation induced in response to HIV [37, 38] . Thus, anti-inflammatory adjunctive therapies may be effective for treating HAND. Although several potential neuroprotective pathways for MVC have been proposed [12] , our results suggest that at least in the context of ART initiation, MVC does not produce unique modulation of the inflammatory pathways underlying HAND beyond what is attributable to control of viral replication or that modulation of these pathways does not lead to a measureable change in neurocognitive function over a short period following ART initiation. MVC may have independent anti-inflammatory effects that were not detected because their magnitude was modest relative to the effects produced by controlling viral replication. Of note, a small open-label single-arm study found neurocognitive improvement among impaired participants whose ART was intensified with MVC [14] .
Another study [39] found that in those with diagnosed HAND on ART, intensification with MVC improved neurocognition over those with no change in ART. A study investigating switching to MVC in participants with HIV-associated neurocognitive impairment found a trend toward neurocognitive improvement [40] . These pilot studies suggest that MVC may confer neurocognitive benefits when used to intensify ART in contrast to our results in ART-naive participants. Notably, studies of the immune effects of MVC have also produced mixed results with a recent open-label MVC intensification study reporting decreased immune activation [41] , whereas a randomized MVC intensification study in those with incomplete CD4 þ restoration found contradictory immune activation effects [42] One possibility is that MVC has several effects, including some that are potentially beneficial to the CNS (such as good CNS penetration and reduction in trafficking of activated T cells and monocytes) counterbalanced by other effects that may not be beneficial.
Neurocognitive impairment remains a relatively prevalent problem in those who are treatment naïve and immunosuppressed, and to some extent in those who are virally suppressed on ART. We found substantial overall neurocognitive improvement on ART regardless of regimen, with 51 of the 104 (49%) impaired participants returning to normal functioning. However, neurocognitive impairment was persistent in some of our participants, 23% of all participants, and 51% of those impaired at baseline, similar to the results of other studies such as CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) [43] . Based on the findings of this study, the largest US-randomized and double-blind trial in HAND to date, inclusion of MVC in initial ART regimens is unlikely to provide unique neurocognitive benefits compared with other potent ART combinations in treatment-naive individuals. A large double-blind randomized placebo-controlled study (ACTG A5324) is ongoing to determine whether MVC has a beneficial effect when used to intensify ART in virologically suppressed HIV-1 patients with neurocognitive impairment.
